Creatine News and Research

RSS

Creatine is an endogenous amino acid which is synthesized from simpler amino acids, namely glycine, arginine and the sulfur-containing amino acid methionine. Approximately 95 percent of creatine in the body is stored in skeletal muscle.

Study assesses effect of combining exercise, dietary supplements on muscle mass and function

Although progressive muscle loss is a natural part of ageing, sarcopenia is generally identified when muscle mass and muscle function falls below defined thresholds.

7 Mar 2017

Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients

There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson's disease (PD) and improve long-term outcomes.

6 Mar 2017

UT Southwestern scientists discover gene that protects gut from IBD

UT Southwestern Medical Center researchers have identified a gene that protects the gut from inflammatory bowel disease.

2 Feb 2017

Johns Hopkins researchers find evidence of brain injury in young NFL players

In a small study of young or recently retired NFL players, researchers at Johns Hopkins report finding evidence of brain injury and repair that is visible on imaging from the players compared to a control group of men without a history of concussion.

29 Nov 2016

Bochum-based scientists explore regeneration measures for athletes in elite sports

In a joint project, Bochum-based researchers headed by Prof Dr Alexander Ferrauti and Prof Dr Michael Kellmann studied the best possible regeneration measures for athletes after strenuous training and competition phases.

2 Aug 2016

TDF reduces vertical HBV transmission

The mother-to-child transmission of hepatitis B virus is reduced with tenofovir disoproxil fumarate treatment during the third trimester in pregnant chronic HBV patients with a high viral load, show the findings of a trial conducted in China.

4 Jul 2016

Study looks at factors that affect physical recovery after participation in ultramarathon

Ultramarathon runners can expect an approximate five-to-seven-day subjective recovery post race, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif. The study also looked at factors that affect physical recovery and a runner's ability to return to full running speed after participation in an ultramarathon.

19 Feb 2016

Compared to monotherapy combination of pills for advanced skin cancer extends survival

The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.3 months)

23 Nov 2015

Sickle cell disease treatment may help protect kidney function in patients

A drug used to treat sickle cell disease may provide an added benefit of protecting patients' kidney function, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

20 Nov 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

New study heightens concerns over detrimental impact of air pollution on gene associated with AD risk

A new study by researchers at the Universities of Montana, Valle de México, Boise State, and North Carolina, the Centro de Ciencias de la Atmósfera, Universidad Nacional Autónoma de México, Instituto Nacional de Pediatría, and Centro Médico Cozumel heightens concerns over the detrimental impact of air pollution on hippocampal metabolites as early markers of neurodegeneration in young urbanites carrying an allele 4 of the apolipoprotein E gene (APOE).

26 Sep 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.

28 Jul 2015

Necrotising autoimmune myopathy requires early, aggressive treatment

Researchers call for the prompt recognition of necrotising autoimmune myopathy and aggressive early treatment with a combination of intravenous immune globulin, corticosteroids and a steroid-sparing agent for 3 months.

27 Jul 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Health food stores promote adult-only dietary supplements to minors

Fifteen year olds are not only able to buy over-the-counter dietary supplements from a sampling of health food stores across the country, the staff at those stores actually went so far as to recommend certain products, despite labels reading "for adult use only."

27 Apr 2015